Related Experiment Video
Updated: Jan 28, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
Chloe Bryson-Cahn1,2, Alison M Beieler1,2, Jeannie D Chan1,2,3
1Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, School of Medicine, Seattle, Washington.
Abstract:
We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.
Related Concept Videos
Secondary Active Transport
Conservation of Small Populations
What is Population Genetics?
Population Growth
Secondary Healthcare System
Primary and Secondary Growth in Roots and Shoots

